Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease
Alzheimer's & Dementia · 2023
DOI: 10.1002/alz.12965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Pei-Jung Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massa…. Hauptthemen laut MEDLINE: Medicaid, Alzheimer Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
Introduction
Ever since the United States Food and Drug Administration (FDA) approved aducanumab and Centers for Medicare & Medicaid Service (CMS) restricted coverage for the drug, a crucial question has been how other payers will behave. This study examined how Medicaid and commercial plans cover aducanumab.
Methods
We created a database of aducanumab coverage policies issued by Medicaid fee‐for‐service programs (50 states and DC) and 35 of the largest commercial plans (covering ∼ 84% of the commercially insured population).
Results
We found that only 41% of Medicaid fee‐for‐service plans have issued a publicly available coverage policy for aducanumab and that there is wide variation in these coverage criteria. Although the majority of included commercial plans have issued an aducanumab coverage policy, only five plans covered aducanumab for their enrollees. Available coverage polices showed little consistency in how to measure sufficient treatment response.
Discussion
Differences in coverage policies mean that Alzheimer's patients’ access to aducanumab may vary across jurisdictions and across commercial insurers. Highlights Less than half of state Medicaid fee‐for‐service plans issued a publicly available coverage policy for aducanumab. Available Medicaid coverage policies varied substantially in their coverage criteria. The majority of included commercial plans issued an aducanumab coverage policy; only five plans covered aducanumab. Available coverage polices showed little consistency in how to measure sufficient treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
- Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.
ORCID-Profile: Pei-Jung Lin
Förderung
- Alzheimer's Association
Zitieren
APA
Lin, P. J., Levine, A., Rucker, J., & Chambers, J. D. (2023). Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12965
Vancouver
Lin PJ, Levine A, Rucker J, Chambers JD. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease. Alzheimer's & Dementia. 2023. doi:10.1002/alz.12965
BibTeX
@article{Lin2023,
author = {Lin, Pei-Jung and Levine, Adele and Rucker, Julia and Chambers, James D},
title = {Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2023},
doi = {10.1002/alz.12965}
}
EUVIMED